Table 1 Properties of the different P2Y12 inhibitors. Adapted and modified from [2, 3]
From: A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease
Clopidogrel | Prasugrel | Ticagrelor | |
|---|---|---|---|
Chemical class | Thienopyridine | Thienopyridine | Cyclopentyl-triazolopyrimidine |
|
|
| |
Administration | Oral | Oral | Oral |
Dose | 300–600 mg orally then 75 mg a day | 60 mg orally then 10 mg a day | 180 mg orally then 90 mg twice a day |
Binding reversibility | Irreversible | Irreversible | Reversible |
Binding site | ADP-binding site | ADP-binding site | Allosteric binding site |
Activation | Prodrug, with variable liver metabolism | Prodrug, with predictable liver metabolism | Active drug, with additional active metabolite |
Onset of loading dose effect | 2–6 h | 30 min | 30 min |
Duration of effect | 3–10 days | 7–10 days | 3–5 days |
Plasma half-life of active P2Y12 inhibitor | 30–60 min | 30–60 min | 6–12 h |
Inhibition of adenosine reuptake | No | No | Yes |
